Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

NIH

Sponsor class

Conditions

Tuberculosis

Interventions

DRUG: PA-824
DRUG: Efavirenz (EFV)
DRUG: Lopinavir/Ritonavir (LPV/r)
DRUG: Rifampin (RIF)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)